References
- Teh BW, Slavin MA, Harrison SJ, et al. Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. Expert Rev Anti Infect Ther. 2015;13(11):1325–1336. doi:10.1586/14787210.2015.1083858.
- Lim C, Sinha P, Harrison SJ, et al. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk. 2021;21(7):444–450.e3. doi:10.1016/j.clml.2021.02.002.
- Sarclisa (isatuximab) [package insert]. Bridgewater (NJ): Sanofi Aventis, US; 2022.
- US Food and Drug Administration. Questions and Answers on FDA's Adverse Event Reporting System. https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed June 30, 2023.
- WHO-UMC system for standardization case causality assessment. Accessed on May 5, 2023 at https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf
- Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. doi:10.1016/S0140-6736(19)32556-5.
- Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371. doi:10.1016/S0140-6736(21)00592-4.
- Vassilopoulos S, Vassilopoulos A, Kalligeros M, et al. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(11):ofac574. doi:10.1093/ofid/ofac574.
- Darzalex (daratumumab) [package insert]. Horsham (PA): Janssen Biotech, Inc.; 2021.
- Glaria E, Valledor AF. Roles of CD38 in the immune response to infection. Cells. 2020;9(1):228. doi:10.3390/cells9010228.